DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Paser (Aminosalicylic Acid) - Published Studies


Paser Related Published Studies

Well-designed clinical trials related to Paser (Aminosalicylic Acid)

Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. [2011.09]

Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: Results from an exploratory randomized controlled trial. [2011.01.06]

Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. [2010.06]

Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. [2009.06.18]

Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. [2007.09]

Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. [2007.07.01]

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. [2006.01]

Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. [2005.06.01]

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. [2004.12]

Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. [2003.10]

Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. [2003.05.01]

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. [2003.01]

Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. [2002.11]

Comparison between nasal and intravenous desmopressin for the treatment of aminosalicylic acid-induced platelet dysfunction. [2002.09]

Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. [2002.02]

Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. [2001.11]

Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis. [2000.09]

The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. [1999.03]

Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. [1997.10]

Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. [1997.07]

Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. [1996.11]

Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. [1996.08]

Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. [1996.06]

Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission. [1996.04]

Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. [1995.12]

Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. [1995.10]

Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. [1995.10]

A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. [1995.04]

Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis. [1994.09]

Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis. [1994.08]

Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. [1994.06]

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). [1994.02]

Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. [1994.01]

Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience. [1994]

Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. [1993.08]

Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. [1993.05]

A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. [1993]

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. [1992.08]

Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis. [1992.07]

A prospective randomized double blind trial comparing prednisolone and 4-aminosalicylic acid enemas in acute distal ulcerative colitis. [1992.03]

Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA). [1992.02]

Topical 5-aminosalicylic acid: a treatment for aphthous ulcers. [1992.02]

Placebo-controlled trial of ulcerative colitis with oral 4-aminosalicylic acid. [1992.02]

[5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. A comparative randomized multicenter trial] [1992]

Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. [1991.08]

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. [1990.11]

5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. [1990.09]

Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity. [1990.09]

Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. [1990.07]

Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. [1990.05]

Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. [1990.05]

Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. [1989.08]

Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. [1989.04]

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. [1989.01.14]

Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. A prospective, randomized, double-blind trial. [1988.10]

5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? [1988.08]

Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. [1988.06]

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. [1988.05]

5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. [1988.04]

Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial. [1988.02]

Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. [1988.02]

Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. [1988.01]

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. [1987.12.24]

[Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy] [1987.10]

5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. [1987.09]

Well-designed clinical trials possibly related to Paser (Aminosalicylic Acid)

Medical management of Crohn's disease. [2011.11]

Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. [2011.04]

A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. [2011.02]

Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. [2011]

Curcumin for inflammatory bowel disease: a review of human studies. [2011]

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. [2010.10]

Efficacy of 5-ASA in the treatment of colonic diverticular disease. [2010.02]

Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. [2009.11]

Efficacy of 5-ASA in the Treatment of Colonic Diverticular Disease. [2009.07.06]

The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. [2009.07]

Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. [2009.07]

Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. [2009.06]

Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. [2009.05]

Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. [2009.03]

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. [2009.02]

Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. [2009.01]

The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. [2008.12.01]

Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. [2008.12]

Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. [2008.10]

Is rosiglitazone a promising treatment for ulcerative colitis? [2008.09]

N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study. [2008.05.14]

Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. [2008.05]

Interventions for treating lymphocytic colitis. [2008.04.16]

A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. [2008.01.07]

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [2007.12]

Successful Treatment of Steroid Refractory Active Ulcerative Colitis with Natural Interferon-beta - an Open Long-Term Trial. [2007.12]

Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. [2007.11.01]

Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up. [2007.11]

Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. [2007.10]

A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. [2007.07]

Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. [2007.06.15]

Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. [2007.06]

Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. [2007.04]

Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. [2007.03]

Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. [2007.03]

Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. [2007.02]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017